Alkermes reports positive Phase 1b data for ADHD drug ALKS 7290
Alkermes announced positive topline results from a Phase 1b proof-of-concept study evaluating its investigational orexin 2 receptor agonist, ALKS 7290, in adults with attention-deficit hyperactivity disorder (ADHD). The drug demonstrated clinically meaningful improvements in ADHD symptoms.